IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies

Cancers (Basel). 2022 May 20;14(10):2526. doi: 10.3390/cancers14102526.

Abstract

Synthesis, folding, and structural maturation of proteins occur in the endoplasmic reticulum (ER). Accumulation of misfolded or unfolded proteins in the ER lumen contributes to the induction of ER stress and activation of the unfolded protein response (UPR) signaling pathway. Under ER stress, the UPR tries to maintain cellular homeostasis through different pathways, including the inositol-requiring enzyme 1 alpha (IRE1α)-dependent ones. IRE1α is located in an ER membrane, and it is evolutionarily the oldest UPR sensor. Activation of IRE1α via ER stress triggers the formation of the spliced form of XBP1 (XBP1s), which has been linked to a pro-survival effect in cancer cells. The role of IRE1α is critical for blood cancer cells, and it was found that the levels of IRE1α and XBP1s are elevated in various hematological malignancies. This review paper is focused on summarizing the latest knowledge about the role of IRE1α and on the assessment of the potential utility of IRE1α inhibitors in blood cancers.

Keywords: X-box-binding protein 1 (XBP1); blood cancer; endoplasmic reticulum stress; inositol-requiring enzyme 1 alpha (IRE1α); leukemia; lymphoma; multiple myeloma; unfolded protein response.

Publication types

  • Review